Last reviewed · How we verify
APG 2575 ramp up arm
At a glance
| Generic name | APG 2575 ramp up arm |
|---|---|
| Also known as | APG2575 |
| Sponsor | Ascentage Pharma Group Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (PHASE1)
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APG 2575 ramp up arm CI brief — competitive landscape report
- APG 2575 ramp up arm updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI